Literature DB >> 10430211

Overview of the epidemiology of malignancy in immune deficiency.

N Mueller1.   

Abstract

Immune-suppressed populations experience higher rates of cancer than expected. The most common malignancies are non-Hodgkin's lymphoma (NHL) in those with HIV infection, in organ transplant recipients, and in those with primary immune deficiencies; Kaposi's sarcoma (KS) in those with HIV infection; and nonmelanoma skin cancer (SC) in transplant patients. These cancers are associated with infection with the Epstein-Barr virus (EBV) in NHL, human herpesvirus type 8 (HHV-8) in KS, and the human papillomaviruses (HPV) in SC. The strength of the association varies from very strong (HHV-8 in KS) to inconsistent (HPV in SC). In HIV infection, the risk of these cancers increases quite gradually (within a few years in almost all of the primary immune deficiencies), whereas this risk increases quite quickly among transplant recipients. Comparing the patterns of malignancy and immune parameters among these immune-incompetent populations and the general population may elucidate the role of host response in controlling latent oncogenic infections.

Entities:  

Mesh:

Year:  1999        PMID: 10430211

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

1.  A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Brenda M Birmann; Ellen T Chang; Donna Spiegelman; Jon C Aster; Shumin M Zhang; Francine Laden
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

Review 2.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

3.  Non-AIDS-Defining Malignancies in the HIV-Infected Population.

Authors:  Chia-Ching J Wang; Michael J Silverberg; Donald I Abrams
Journal:  Curr Infect Dis Rep       Date:  2014-06       Impact factor: 3.725

4.  Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice.

Authors:  G T Belz; P G Stevenson; M R Castrucci; J D Altman; P C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

5.  Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression.

Authors:  D Dréau; C Culberson; S Wyatt; W D Holder
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

6.  Cryo-electron tomography of Kaposi's sarcoma-associated herpesvirus capsids reveals dynamic scaffolding structures essential to capsid assembly and maturation.

Authors:  Binbin Deng; Christine M O'Connor; Dean H Kedes; Z Hong Zhou
Journal:  J Struct Biol       Date:  2007-11-17       Impact factor: 2.867

7.  Unique structures in a tumor herpesvirus revealed by cryo-electron tomography and microscopy.

Authors:  Wei Dai; Qingmei Jia; Eric Bortz; Sanket Shah; Jun Liu; Ivo Atanasov; Xudong Li; Kenneth A Taylor; Ren Sun; Z Hong Zhou
Journal:  J Struct Biol       Date:  2007-11-20       Impact factor: 2.867

8.  Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.

Authors:  Molykutty J Aryankalayil; Adeola Y Makinde; Sofia R Gameiro; James W Hodge; Patricia P Rivera-Solis; Sanjeewani T Palayoor; Mansoor M Ahmed; C Norman Coleman
Journal:  Radiat Res       Date:  2014-07-08       Impact factor: 2.841

9.  Three-dimensional structures of the A, B, and C capsids of rhesus monkey rhadinovirus: insights into gammaherpesvirus capsid assembly, maturation, and DNA packaging.

Authors:  Xue-Kui Yu; Christine M O'Connor; Ivo Atanasov; Blossom Damania; Dean H Kedes; Z Hong Zhou
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  How does ionizing irradiation contribute to the induction of anti-tumor immunity?

Authors:  Yvonne Rubner; Roland Wunderlich; Paul-Friedrich Rühle; Lorenz Kulzer; Nina Werthmöller; Benjamin Frey; Eva-Maria Weiss; Ludwig Keilholz; Rainer Fietkau; Udo S Gaipl
Journal:  Front Oncol       Date:  2012-07-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.